News
Important Only
Slide Insurance launches 20 million share IPO on Nasdaq
June 9 - (The Insurer) - Slide Insurance on Monday announced an initial public offering of 20 million shares which it expects to be priced between $15 and $17 each on the Nasdaq Global Select Market, potentially raising as much as $340 million.Tampa-based Slide, which was founded by Bruce and Shanno...Reuters
Mon, Jun 9
AIG Announces Results And Upsizing Of Its Tender Offers For Certain Outstanding Notes
June 9 (Reuters) - American International Group Inc AIG.N:AIG ANNOUNCES RESULTS AND UPSIZING OF ITS TENDER OFFERS FOR CERTAIN OUTSTANDING NOTESAMERICAN INTERNATIONAL GROUP INC - UPSIZES TENDER OFFERS TO $455 MILLIONReuters
Mon, Jun 9
HUB International Strengthens Wealth Management Services With Acquisition Of Veripax Wealth Management, In California
June 9 (Reuters) - HUB International Ltd [RIC:RIC:HBINT.UL]:HUB INTERNATIONAL STRENGTHENS WEALTH MANAGEMENT SERVICES WITH ACQUISITION OF VERIPAX WEALTH MANAGEMENT, INC. IN CALIFORNIAHUB INTERNATIONAL LTD - TERMS OF HUB-VWM DEAL NOT DISCLOSEDFurther company coverage: HBINT.ULReuters
Mon, Jun 9
Mckesson Says Executives To Meet With Investors And Analysts - SEC Filing
June 9 (Reuters) - Mckesson Corp MCK.N:MCKESSON CORP - EXECUTIVES TO MEET WITH INVESTORS AND ANALYSTS - SEC FILINGMCKESSON CORP - INCREASES FY 2026 ADJUSTED EPS GUIDANCE TO $36.90-$37.70 - SEC FILINGSource text: [ID:n0000927653-25-000045]Reuters
Mon, Jun 9
Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
June 9 (Reuters) - Elevation Oncology Inc ELEV.O:ELEVATION ONCOLOGY ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $0.36 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHTELEVATION ONCOLOGY INC - CONCENTRA TO BUY ELEVATION ONCOLOGY FOR $0.36 PER SHARE PLUS CVRELEVATION ONCOLOGY INC -...Reuters
Mon, Jun 9
Anixa Biosciences Announces Poster Presentation On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025
June 9 (Reuters) - Anixa Biosciences Inc ANIX.O:ANIXA BIOSCIENCES ANNOUNCES POSTER PRESENTATION ON OVARIAN CANCER CAR-T CLINICAL TRIAL AT THE ESMO GYNAECOLOGICAL CANCERS CONGRESS 2025Reuters
Mon, Jun 9
FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma
June 9 (Reuters) - TuHURA Biosciences Inc HURA.O:FDA REMOVES PARTIAL CLINICAL HOLD ON TUHURA BIOSCIENCES' PHASE 3 ACCELERATED APPROVAL TRIAL FOR IFX-2.0 IN ADVANCED OR METASTATIC MERKEL CELL CARCINOMAReuters
Mon, Jun 9
DESTINY-Endometrial01 Phase 3 Trial Of ENHERTU® Initiated As First-Line Therapy In Patients With HER2 Expressing Primary Advanced Or Recurrent Endometrial Cancer
June 9 (Reuters) - Daiichi Sankyo Co Ltd 4568.T:DESTINY-ENDOMETRIAL01 PHASE 3 TRIAL OF ENHERTU® INITIATED AS FIRST-LINE THERAPY IN PATIENTS WITH HER2 EXPRESSING PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCERReuters
Mon, Jun 9
Eagle Point Income Company Authorizes $50 Million Stock Repurchase Program
June 9 (Reuters) - Eagle Point Income Company Inc EIC.N:EAGLE POINT INCOME COMPANY INC. ANNOUNCES COMMON STOCK REPURCHASE PROGRAMEAGLE POINT INCOME COMPANY INC - AUTHORIZES $50 MILLION STOCK REPURCHASE PROGRAMReuters
Mon, Jun 9
SailPoint Inc expected to post breakeven results a share - Earnings Preview
SailPoint Inc SAIL.OQ SAIL.O is expected to report resultson June 11 for the period ending October 31 2024The Austin Texas-based company is expected to report revenue of $235.187 million, according to the mean estimate from 3 analysts, based on LSEG data.LSEG's mean analyst estimate for SailPo...Reuters
Mon, Jun 9
